Reuters Health Information: Achillion's hepatitis C drug cures all patients in mid-stage trial
Achillion's hepatitis C drug cures all patients in mid-stage trial
Last Updated: 2014-08-15
By Reutes Staff
(Reuters) - Achillion Pharmaceuticals Inc said interim
results from a mid-stage trial showed that all patients given
its experimental hepatitis C drug showed no detectable levels of
the virus four weeks after completing the therapy.
The mid-stage trial tested Achillion's second-generation
NS5A inhibitor ACH-3102 in 12 patients in combination with
sofosbuvir (Sovaldi) from Gilead Sciences.
Achillion said it would begin treating 12 additional
patients for six weeks with a once-daily dose of ACH-3102 and
The trial excluded the older hepatitis C drug ribavirin,
which can cause rashes, anemia and other side effects.